Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675614 | 0.89 | HSD11B1 (0.38) | HSD11B1P2RX7 | |
| SCHEMBL4522631 | 0.78 | HSD11B1 (0.39) | HSD11B1ROCK2 | |
| SCHEMBL4513997 | 0.77 | HSD11B1 (0.41) | HSD11B1P2RX7ROCK2 | |
| SCHEMBL12432122 | 0.75 | HSD11B1 (0.41) | HSD11B1P2RX7ROCK2EPHX2 | |
| SCHEMBL4511421 | 0.75 | HSD11B1 (0.41) | HSD11B1P2RX7ROCK2 | |
| SCHEMBL2208659 | 0.75 | HSD11B1 (0.43) | HSD11B1P2RX7GPBAR1EPHX2 | |
| SCHEMBL4525789 | 0.75 | HSD11B1 (0.51) | HSD11B1ROCK2GPBAR1 | |
| SCHEMBL4523771 | 0.74 | HSD11B1 (0.45) | HSD11B1ROCK2 | |
| SCHEMBL2206955 | 0.74 | P2RX7 (0.43) | HSD11B1P2RX7CYP2C9 | |
| SCHEMBL2204952 | 0.73 | OPRM1 (0.42) | HSD11B1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885P2RX7 3946/4885ROCK2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.